News » KYOCERA to Purchase Major Assets of U.S.-based Renovis Surgical Technologies, Inc.

News

KYOCERA to Purchase Major Assets of U.S.-based Renovis Surgical Technologies, Inc.

Kyocera Corporation (President: Hideo Tanimoto) today announced that its U.S.
headquarters, Kyocera International, Inc., has finalized an agreement with Renovis Surgical
Technologies, Inc. (herein “Renovis”), a U.S.-based orthopedic and spinal medical device
manufacturer and developer, to purchase the major assets of Renovis’ business operations
relating to artificial joint and spinal products.

The assets will be transferred into a new California-based company wholly owned by Kyocera
International, Inc., to be named Kyocera Medical Technologies, Inc., in March 2019.

Background and Overview
Kyocera currently manufactures medical products, including artificial joints and dental
implants, primarily for the Japanese market. The U.S. orthopedic implant market totals
approximately US$20 billion, representing about 60% of the global market, with continued
growth expected.* To grow internationally, Kyocera obtained U.S. FDA 510(k) clearance for its
artificial hip joints and began selling them in the U.S. in 2017.

Renovis, founded in 2009, is a market leader in 3D-printed implants, and has developed a
broad portfolio of innovative products for the U.S. market, serving the needs of orthopedic,
neurological, and trauma surgeons. Renovis has experienced steady growth since its
inception and has continued to develop and commercialize a wide range of products
manufactured using its Tesera Trabecular Technology, a proprietary implant surface structure
made using additive manufacturing. In addition, Renovis has developed an advanced bearing
surface technology for joint replacement products. Kyocera’s global strength and expansive
research and development capabilities will accelerate the growth of these valuable
technologies.

Kyocera plans to expand its U.S. medical equipment business through this asset purchase.
The newly established company will develop high value-added products that improve patient
health and quality of life through synergies between Kyocera’s proprietary technologies and
those purchased from Renovis.

* Based on third-party research as of December 2018

Overview of Renovis
Company name: Renovis Surgical Technologies, Inc.
Location Headquarters: Redlands, California, U.S.A.
Development center: Austin, Texas, U.S.A.
President and CEO John C. Steinmann
Employees 44 (as of December 31, 2018)


Top of page